Zobrazeno 1 - 10
of 221
pro vyhledávání: '"Roger F. Soll"'
Autor:
Bernard Thébaud, Manoj Lalu, Laurent Renesme, Sasha vanKatwyk, Justin Presseau, Kednapa Thavorn, Kelly D. Cobey, Brian Hutton, David Moher, Roger F. Soll, Dean Fergusson
Publikováno v:
Stem Cells Translational Medicine, Vol 10, Iss 7, Pp 968-975 (2021)
Abstract Cell‐based therapies hold promise to substantially curb complications from extreme preterm birth, the main cause of death in children below the age of 5 years. Exciting preclinical studies in experimental neonatal lung injury have provided
Externí odkaz:
https://doaj.org/article/2791354e597442ad92ae5be3758ae715
Autor:
Martin Offringa, Anton H van Kaam, Wes Onland, Prakesh S Shah, Erik A Jensen, Rosemary D Higgins, Trixie A Katz, J Jane Pillow, Tetsuya Isayama, Benjamin Stoecklin, Sanne J Gordijn, Eduardo Bancalari, Roger F Soll, Suzanne M Mugie
Publikováno v:
BMJ Paediatrics Open, Vol 7, Iss 1 (2023)
Introduction Bronchopulmonary dysplasia (BPD) remains the most common complication of preterm birth with lifelong consequences. Multiple BPD definitions are currently used in daily practice. Uniformity in defining BPD is important for clinical care,
Externí odkaz:
https://doaj.org/article/daca03c6f0ad40ae8dba6016f09b83e2
Autor:
Katherine Culbreath, Jamie Knell, Gregory Keefe, Emily Nes, Sam M. Han, Erika M. Edwards, Kate A. Morrow, Roger F. Soll, Tom Jaksic, Jeffrey D. Horbar, Biren P. Modi
Publikováno v:
Journal of Perinatology. 43:91-96
Autor:
Roger F. Soll, Petter Brattström, Chiara Russo, Matteo Bruschettini, Wes Onland, Peter G Davis
Publikováno v:
Cochrane Database of Systematic Reviews, 2021(2):CD013873. John Wiley and Sons Ltd
BACKGROUND: Very preterm infants often require respiratory support and are therefore exposed to an increased risk of bronchopulmonary dysplasia (chronic lung disease) and later neurodevelopmental disability. Caffeine is widely used to prevent and tre
Autor:
Yarden S, Fraiman, Erika M, Edwards, Jeffrey D, Horbar, Charles E, Mercier, Roger F, Soll, Jonathan S, Litt
Publikováno v:
Pediatrics. 151
BACKGROUND AND OBJECTIVES High-risk infant follow-up programs (HRIFs) are a recommended standard of care for all extremely low birth weight (ELBW) infants to help mitigate known risks to long-term health and development. However, participation is var
Autor:
Erin N. O’Leary, Jonathan R. Edwards, Arjun Srinivasan, Melinda M. Neuhauser, Minn M. Soe, Amy K. Webb, Erika M. Edwards, Jeffrey D. Horbar, Roger F. Soll, Jessica Roberts, Lauri A. Hicks, Hsiu Wu, Denise Zayack, David Braun, Susan Cali, William H. Edwards, Dustin D. Flannery, Katherine E. Fleming-Dutra, Judith A. Guzman-Cottrill, Michael Kuzniewicz, Grace M. Lee, Jason Newland, Jared Olson, Karen M. Puopolo, Stefanie P. Rogers, Joseph Schulman, Edward Septimus, Daniel A. Pollock
Publikováno v:
Hospital Pediatrics. 12:190-198
BACKGROUND The microbiologic etiologies, clinical manifestations, and antimicrobial treatment of neonatal infections differ substantially from infections in adult and pediatric patient populations. In 2019, the Centers for Disease Control and Prevent
Autor:
Leila Agha, Douglas Staiger, Christopher Brown, Roger F. Soll, Jeffrey D. Horbar, Erika M. Edwards
Publikováno v:
JAMA Health Forum. 4:e230960
ImportanceFor neonates with very low birth weight (VLBW), randomized clinical trials (RCTs) indicate that probiotic treatment decreases the risk of necrotizing enterocolitis (NEC), with smaller decreases in the risk of sepsis and death. There is litt
Autor:
Elizabeth Reid, Omar F Kamlin, Francesca Orsini, Antonio G De Paoli, Howard W Clark, Roger F Soll, John B Carlin, Peter G Davis, Peter A Dargaville
Publikováno v:
Clinical Trials. :174077452311716
Background: Blinding of treatment allocation from treating clinicians in neonatal randomised controlled trials can minimise performance bias, but its effectiveness is rarely assessed. Methods: To examine the effectiveness of blinding a procedural int
Autor:
Roger F. Soll
Publikováno v:
JAMA
IMPORTANCE: Laser photocoagulation, which is the standard treatment for retinopathy of prematurity (ROP), can have adverse events. Studies of anti–vascular endothelial growth factor injections have suggested efficacy in the treatment of ROP, but fe
Autor:
Justin Presseau, Laurent Renesme, Kelly Cobey, Dean Fergusson, David Moher, Roger F. Soll, Sasha van Katwyk, Manoj M. Lalu, Bernard Thébaud, Brian Hutton, Kednapa Thavorn
Publikováno v:
Stem Cells Translational Medicine, Vol 10, Iss 7, Pp 968-975 (2021)
Stem Cells Translational Medicine
Stem Cells Translational Medicine
Cell‐based therapies hold promise to substantially curb complications from extreme preterm birth, the main cause of death in children below the age of 5 years. Exciting preclinical studies in experimental neonatal lung injury have provided the impe